

AI-driven Drug Discovery Startup MOLCURE Raises \$7.2 million in Series C Funding

Accelerating business partnerships internationally

KAWASAKI, JAPAN – Aug 18, 2021– MOLCURE, an AI-driven drug discovery and developing company, has raised \$ 7.2 million in Series C funding. The round was led by Jafco Group and the participation of STRIVE, SBI Investment, Japan Post Capital, and previous investors GMO Venture Partners and Nippon Chemiphar.



Background and purpose of fundraising

MOLCURE is a growing startup company with a unique biopharmaceutical molecular design technology that makes full use of Artificial Intelligence (AI). Collaborating with pharmaceutical companies, MOLCURE accelerates drug discovery by developing novel drug candidate molecules. MOLCURE’s patented and validated AI platform is based on evolutionary molecular engineering, next-generation sequencing (NGS), and laboratory automation technologies.

“Projects with partners conducted in 2021 produced significant results.” said Ryu Ogawa, Ph.D., CEO and co-founder of MOLCURE. “In one project, we were successful in generating great numbers of lead molecules with more than 100 times higher binding strength compared with conventional biotechnology experiment-driven methods. In another project, we succeeded, for the first time in the world, designing a molecule with an effect on a difficult drug target. With this new investment, we continue to further develop our technology, scaling capacity, and expanding teams to accelerate strategic partnerships with international pharmaceutical companies.”

10 times Diverse & High-Performance Biopharmaceutical Drug Discovery

Maximizing results from the laboratory with AI

Our patented technology



MOLCURE uses NGS to generate big data from the samples collected from evolutionary molecular engineering experiments and uses AI technology to refine the selection of high-quality biopharmaceutical candidates.

MOLCURE has already collaborated on more than ten projects with multiple pharmaceutical and biotech partners, including Twist Bioscience ([*See press release July 27, 2021](#)), and Nippon Chemiphar.



MOLCURE will continue to improve and expand the technology with cutting-edge technologies to develop new generations of safer and more effective treatments for patients around the world.

About MOLCURE

MOLCURE is an AI-driven drug discovery and development company. The company's patented and validated AI platform is based on evolutionary molecular engineering, next-generation sequencing (NGS), and laboratory automation technologies. The technology enables to design ten times superior molecules, and the number of new molecules generated is more than twenty times compared with conventional methods.

MOLCURE is headquartered in KAWASAKI (JP) with a research facility at TSURUOKA (JP).

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#)

CONTACT

Aya Saitoh

contact@molcure.io